Hodgkin lymphoma accounts for approximately 10 percent of all lymphomas and approximately 0.6 percent of all cancers diagnosed in the developed world annually. This amounts to approximately 8830 new cases and about 1300 deaths due to HL in the United States annually.
The majority of patients with classical Hodgkin lymphoma present with painless localized enlarged lymph nodes, typically involving the cervical (neck) region.
Hodgkin lymphoma arises from germinal center or post-germinal center B cells in the lymph nodes. Hodgkin lymphoma has a unique cellular composition, containing a minority of neoplastic cells (Reed-Sternberg cells and their variants) in an inflammatory background. It is separated from the other B cell lymphomas based on its unique clinicopathologic features, and can be divided into two major sub-groups, based on the appearance and immunophenotype of the tumor cells.
The diagnosis of Hodgkin lymphoma is made by the evaluation of involved tissue, usually a lymph node biopsy. Excisional biopsies are preferred and large core needle biopsies may be adequate in select cases.
Here, Dr. Tony Talebi discusses the general concepts of Hodgkin lymphoma with Dr. Ann Morhbacher, associate professor of medicine at the University of Southern California and a "top US doctor" as per US world news and world report magazine. The discussion includes symptoms, diagnosis, staging, genetic implications, secondary cancers, treatment of hodgkin lymphoma,Lymphomaprognosis, what causeslymphoma, signs oflymphoma, lymphomasymptoms, lymphoma, lymphomastage 4, treatment oflymphoma, lymphomaassociation, stage fourlymphoma, small celllymphoma, symtoms oflymphoma, causes oflymphoma, lymphomachemotherapy, what islymphoma, lymphomas, lymphomainformation, lymphomaprevention, stage 4lymphoma, information aboutlymphoma, stage ivlymphoma, lymphomasigns, lymphomasymptom, islymphomacurable, stage 3blymphoma, lungs cancer symptoms, survival
rates forlymphoma, symptoms oflymphoma, lymphomasurvivors, lymphomasymptons, lymphomasurvival, treatments oflymphoma, symptons oflymphoma, lymphomastatistics, non small celllymphoma, chemo forlymphoma, lymphomasurvival rate, large celllymphoma, effects oflymphoma, lymphomascreening, lymphomadiagnosis, lymphomasociety,
lymphomaclinical trials, lymphomametastasis, survival ratelymphoma, symptom oflymphoma, info onlymphoma, new treatments forlymphoma, how common islymphoma.
.
Dr. Ann Morhbacher credentials:
Title:
Associate Professor of Clinical Medicine
Locations:
University of Southern California (USC) Norris Comprehensive Cancer Center
Specialties:
Hematology and Oncology
Background:
Dr. Mohrbacher, a graduate of Harvard Medical School, is a devoted educator, researcher and medical practitioner. She has several hematology related research interests and activities, including bone marrow transplantation, and has received thousands of dollars in research grants. She has been published in a number of medical journals and has been invited to lecture on topics including Radioimmunotherapy of non-Hodgkin’s lymphoma and B-cell targeted therapy of rheumatoid arthritis. Dr. Mohrbacher is a member of the Southern California Lymphoma Group and currently belongs to a number of university related committees, such as the Post-Graduate Education Committee and the Clinical Investigations Committee.
Education:
Harvard and Radcliffe Colleges, Boston, MA, B.A., 1983
Doctor of Medicine, Harvard Medical School, Boston, MA, 1987
Internships:
Brigham and Women's Hospital, Boston, MA, 1983 - 1984
